Published Scientific Research
The International Hyperhidrosis Society was founded in 2003 by a group of dedicated physicians and medical professionals with a commitment to scientific rigor in hyperhidrosis and related fields. As part of that commitment, we keep an extensive inventory of published scientific literature relevant to hyperhidrosis and share it with you, here. We believe it's vital to review published clinical data whenever discussing or reporting on health and hyperhidrosis and we strongly encourage product and treatment development teams to conduct rigorous testing and to espouse only that which can be validated.
Below you will find chronological links to articles, posters, and study data representing the most current peer-reviewed medical and scientific information available on the physiology, treatment, and effects of hyperhidrosis. New data will be posted as it becomes available. Use this rich library of research to inform your decisions and perceptions.
Are you working on research in hyperhidrosis? We can help in many ways!
And, as always, your donations are vital to our continued, collective work toward better care, improved lives, and greater understanding.
We do our best to scour all publications and post hyperhidrosis research here, but if we have missed something, please let us know. We will be happy to include it!
Albucker SJ, Lipner SR. Microwave energy devices for hyperhidrosis are associated with infections, neurologic symptoms, and burns in a retrospective analysis of the Manufacturer and User Facility Device Experience database 2013-2022 [published online ahead of print, 2023 Jun 7]. J Am Acad Dermatol. 2023;S0190-9622(23)01015-0. doi:10.1016/j.jaad.2023.06.005
Fujimoto T, Terahara T, Okawa K, Inakura H, Hirayama Y, Yokozeki H. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study. J Am Acad Dermatol. 2023;89(1):62-69. doi:10.1016/j.jaad.2023.03.025 (Abstract Only)
Glaser D, Green L, Kaminer M, Smith S, Pariser D. Outcomes from the SAHARA clinical study on the TAT patch for excessive axillary sweating or primary axillary hyperhidrosis. Poster presented at the Music City SCALE 2023; May 17-21, 2023; Nashville, TN.
Han JW, Ahn S, Jeong JY, Park CB, Eom E, Park SS. Use of thoracoscopy for thoracic sympathetic nerve block in primary hyperhidrosis. Sci Rep. 2023;13(1):1402. Published 2023 Jan 25. doi:10.1038/s41598-023-28727-5
Jacob C, Day D. Primary axillary hyperhidrosis or excessive axillary sweating in aesthetics patients: prevalent, mostly undiagnosed, embarrassing, impairs quality of life, demonstrates need for new treatment. Poster presented at the Cosmetic Bootcamp Summer Meeting 2023; June 22-25, 2023; Aspen, CO.
Jacob C, Green L. Quality of life improvement shown during SAHARA clinical study on the TAT patch for the treatment of primary axillary hyperhidrosis or excessive axillary sweating. Poster presented at the Cosmetic Bootcamp Summer Meeting 2023; June 22-25, 2023; Aspen, CO.
Kravitz SA, Lannan FM, Simpson MM. Long-term Effectiveness of Microwave Thermoablation in Persons With Residual Limb Hyperhidrosis: A Case Series. Mil Med. 2023;188(1-2):e417-e420. doi:10.1093/milmed/usab083 (Abstract Only)
Oshima Y, Fujimoto T, Nomoto M, Fukui J, Ikoma A. Hyperhidrosis: A targeted literature review of the disease burden [published online ahead of print, 2023 Jul 31]. J Dermatol. 2023;10.1111/1346-8138.16908. doi:10.1111/1346-8138.16908 (Abstract Only)
Rocha Melo J, Rodrigues MA, Caetano M, Cantista P. Botulinum toxin in the treatment of residual limb hyperhidrosis: A systematic review [published online ahead of print, 2023 Feb 13]. Rehabilitacion (Madr). 2023;57(3):100754. doi:10.1016/j.rh.2022.07.003 (Abstract Only)
Saki N, Shakouri N, Rastaghi F, Hosseini SA, Alipour S, Ahramiyanpour N. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial. J Cosmet Dermatol. 2023;22(8):2268-2272. doi:10.1111/jocd.15715
Szeimies RM, Abels C, Kilic A, et al. Long-term efficacy and safety of 1% glycopyrronium bromide cream in patients with severe primary axillary hyperhidrosis: Results from a Phase 3b trial [published online ahead of print, 2023 Jan 6]. J Eur Acad Dermatol Venereol. 2023;10.1111/jdv.18843. doi:10.1111/jdv.18843
Taudorf EH, Henning M, Olsen J, Thorlacius L, Christensen R, Jemec G. Attempted treatment of primary axillary hyperhidrosis with one session of either Neodymium YAG laser or Intense Pulsed Light: A within patient randomized trial of treated versus untreated contralateral axilla. Lasers Surg Med. 2023;55(8):748-757. doi:10.1002/lsm.23697 (Abstract Only)
Ando Y, Ohshima Y, Yanagishita T, et al. Clinical utility of botulinum toxin type A local injection therapy for head and forehead hyperhidrosis. J Dermatol. 2022;49(7):719-723. doi:10.1111/1346-8138.16368 (Abstract Only)
Collercandy N, Thorey C, Diot E, et al. When to investigate for secondary hyperhidrosis: data from a retrospective cohort of all causes of recurrent sweating. Ann Med. 2022;54(1):2089-2101. doi:10.1080/07853890.2022.2102675
de Campos AM, Silva RR, Calegaro ML, Raymundo-Pereira PA. Design and Fabrication of Flexible Copper Sensor Decorated with Bismuth Micro/Nanodentrites to Detect Lead and Cadmium in Noninvasive Samples of Sweat. Chemosensors. 2022; 10(11):446. doi.org/10.3390/chemosensors10110446
Ebrahim H, Nassar A, Mousa MM, Khater E. Microneedling Delivery of Botulinum Toxin Versus Intradermal Injection in the Treatment of Facial Hyperhidrosis. J Clin Aesthet Dermatol. 2022;15(9):40-44. (Abstract Only)
Fujimoto T, Okatsu H, Miyama H. Two-week prospective observational study of 5% sofpironium bromide gel in Japanese patients with primary axillary hyperhidrosis [published correction appears in J Dermatol. 2022 Aug;49(8):800]. J Dermatol. 2022;49(6):594-599. doi:10.1111/1346-8138.16384
Gregoriou S, Tsiogka A, Kontochristopoulos G, Offidani A, Campanati A. Sofpironium bromide: an investigational agent for the treatment of axillary hyperhidrosis. Expert Opin Investig Drugs. 2022;31(1):15-21. doi:10.1080/13543784.2022.2017880 (Abstract Only)
Heiskanen SL, Niskala J, Jokelainen J, Tasanen K, Huilaja L, Sinikumpu SP. Hyperhidrosis Comorbidities and Treatments: A Register-based Study among 511 Subjects. Acta Derm Venereol. 2022;102:adv00656. Published 2022 Feb 28. doi:10.2340/actadv.v102.1061
Jung JM, Na HM, Kim JH, et al. The efficacy and safety of a fractional microneedle radiofrequency device for the treatment of axillary hyperhidrosis: clinical prospective pilot study. Lasers Med Sci. 2022;37(3):1559-1566. doi:10.1007/s10103-021-03404-z (Abstract Only)
Kaufman J, Green JB, Cazzaniga A, Canty DJ, Tims E, Waugh J. A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects With Axillary Hyperhidrosis. Dermatol Surg. 2022 Nov 1;48(11):1220-1225. doi: 10.1097/DSS.0000000000003598. Epub 2022
Kotitsas P, Tsiogka A, Agiasofitou E, et al. Residual limb hyperhidrosis successfully managed with topical glycopyrrolate. Indian J Dermatol Venereol Leprol. 2022;88(2):230-231. doi:10.25259/IJDVL_132_2021
Lee DG, Kim JE, Lee WS, et al. A Phase 3, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Neu-BoNT/A in Treatment of Primary Axillary Hyperhidrosis. Aesthetic Plast Surg. 2022;46(3):1400-1406. doi:10.1007/s00266-021-02715-4 (Abstract Only)
J. Lin, R. Ou, Q. Wei, B. Cao, C. Li, Y. Hou, L. Zhang, K. Liu, H. Shang. Hyperhidrosis in Parkinson's disease: a 3-year prospective cohort study. Journal of The European Academy of Dermatology and Venereology (JEADV). 13 March 2022; https://doi.org/10.1111/jdv.18072
Nofal E, Salem S, Khashaba SA. Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature. Dermatol Surg. 2022;48(8):843-848. doi:10.1097/DSS.0000000000003490 (Abstract Only)
Pitliuk R, Coelho CMF, Fucci TPPDCS. Unexpected improvement of hyperhidrosis with cannabidiol. Einstein (Sao Paulo). 2022;20:eRC5795. Published 2022 Feb 8. doi:10.31744/einstein_journal/2022RC5795
Raveglia F, Orlandi R, Guttadauro A, et al. How to Prevent, Reduce, and Treat Severe Post Sympathetic Chain Compensatory Hyperhidrosis: 2021 State of the Art. Front Surg. 2022;8:814916. Published 2022 Jan 3. doi:10.3389/fsurg.2021.814916
Woo W, Oh J, Kim BJ, Won J, Moon DH, Lee S. The Impact of COVID-19 on Hyperhidrosis Patients in the Mental Health and Quality of Life: A Web-Based Surveillance Study. J Clin Med. 2022;11(13):3576. Published 2022 Jun 21. doi:10.3390/jcm11133576
Zhang D, Zhuang W, Lan Z, et al. Long-term follow-up in quality of life before and after endoscopic thoracic sympathicotomy in 367 patients with palmar hyperhidrosis. Ann Palliat Med. 2022;11(6):1961-1968. doi:10.21037/apm-21-2860 (Abstract Only)
Zhang Y, Gong YY, Tang YL, et al. Clinical efficacy of microwave in the treatment of axillary osmidrosis and primary hyperhidrosis. Dermatol Ther. 2022;35(8):e15657. doi:10.1111/dth.15657 (Abstract Only)
Abels C, Soeberdt M, Kilic A, et al. A 1% glycopyrronium bromide cream for the topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase 3a randomised controlled study [published online ahead of print, 2021 Jan 14]. Br J Dermatol. 2021;10.1111/bjd.19810. doi:10.1111/bjd.19810
Chang TN, Daniel BW, Hsu AT, et al. Reversal of thoracic sympathectomy through robot-assisted microsurgical sympathetic trunk reconstruction with sural nerve graft and additional end-to-side coaptation of the intercostal nerves: A case report. Microsurgery. 2021;41(8):772-776. doi:10.1002/micr.30787 (Abstract Only)
Ezure T, Amano S, Matsuzaki K. Aging-related shift of eccrine sweat glands toward the skin surface due to tangling and rotation of the secretory ducts revealed by digital 3D skin reconstruction. Skin Res Technol. 2021;27(4):569-575. doi:10.1111/srt.12985 (Abstract Only)
Fujimoto T, Abe Y, Igarashi M, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis [published online ahead of print, 2021 May 26]. J Dermatol. 2021;10.1111/1346-8138.15927. doi:10.1111/1346-8138.15927
Gregoriou S, Campanati A, Rigopoulos D, Maria Offidani A, Stratigos A, Kontochristoulos G. Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis. Expert Opin Investig Drugs. 2021;30(5):479-482. doi:10.1080/13543784.2021.1900114 (Abstract Not Available)
Gregoriou S, Kontochristopoulos G, Tiligada E. Pharmacokinetic profile data of glycopyrronium bromide 1% cream beyond 2 weeks are important. Br J Dermatol. 2021;185(2):467-468. doi:10.1111/bjd.20088 (Abstract Not Available)
Gregoriou S, Markantoni V, Campanati A, et al. Treatment of Axillary Bromhidrosis with Topical 2% Glycopyrronium Bromide Cream: A Prospective, Non-randomized, Open-label Study. J Clin Aesthet Dermatol. 2021;14(11):E61-E63.
Hur, K.J., Moon, H.W., Park, Y.H. et al. Retroperitoneoscopic lumbar sympathectomy for the treatment of primary plantar hyperhidrosis. BMC Surg 21, 397 (2021). https://doi.org/10.1186/s12893-021-01393-y
Kirsch B, DuBois J, Zaiac M, Ahuja S, Chadha D. A multi-center, open-label extension study to assess the long-term safety, tolerability and pharmacokinetics, and explore the efficacy of sofpironium bromide gel, 15% applied topically to children and adolescents, 9 to 16 years of age, with primary axillary hyperhidrosis (BBI-4000-CL-108). Poster presented virtually at the 2021 Masters of Pediatric Dermatology conference; February 4-5, 2021.
Kontochristopoulos G, Markantoni V, Agiasofitou E, et al. Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin chloride 10. J Eur Acad Dermatol Venereol. 2021;35(8):e524-e526. doi:10.1111/jdv.17297 (Abstract Not Available)
Lannan FM, Powell J, Kim GM, Hansen CR, Pasquina PF, Smith DG. Hyperhidrosis of the residual limb: a narrative review of the measurement and treatment of excess perspiration affecting individuals with amputation. Prosthet Orthot Int. 2021;45(6):477-486. doi:10.1097/PXR.0000000000000040 (Abstract Only)
Malik AS, Porter CL, Feldman SR. Bromhidrosis Treatment Modalities: A Literature Review [published online ahead of print, 2021 Jan 19]. J Am Acad Dermatol. 2021;S0190-9622(21)00175-4. doi:10.1016/j.jaad.2021.01.030 (Abstract Only)
Pariser DM, Lain EL, Mamelok RD, Drew J, Mould DR. Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis [published online ahead of print, 2021 Jan 12]. Clin Pharmacokinet. 2021;10.1007/s40262-020-00975-y. doi:10.1007/s40262-020-00975-y
Park HH, Conic RR, Zhang S, Lieu A, Haft M, Hightower GK. Oral glycopyrrolate for primary focal hyperhidrosis in pediatric population: a cross-sectional study [published online ahead of print, 2021 July]. JAAD International 4 (2021): 65-66. doi: 10.1016/j.jdin.2021.07.002
Remington C, Ruth J, Hebert AA. Primary hyperhidrosis in children: A review of therapeutics [published online ahead of print, 2021 Mar 4]. Pediatr Dermatol. 2021;10.1111/pde.14551. doi:10.1111/pde.14551 (Abstract Only)
Rice ZP, Sidbury R, Pieretti LJ, Devlin T, Gillard KK, Comoroda D, Kosinski M, Hebert AA. Hyperhidrosis affects multiple focal areas and is undertreated in pediatric sufferers: survey results from population of > 500 children and adolescents (ages 6-18). Poster presented virtually at the 19th Annual South Beach Symposium; February 4-7, 2021.
Rice ZP, Sidbury R, Pieretti LJ, Devlin T, Gillard KK, Comoroda D, Kosinski M, Hebert AA. Hyperhidrosis awareness and treatment in pediatric sufferers: survey results from a population of >500 children and adolescents (Ages 6-18). Poster presented virtually at the 42nd Annual Conference of the National Association of Pediatric Nurse Practitioners; March 24-27, 2021.
Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Sidbury R, Hebert AA. Clinical presentation and quality of life burden associated with hyperhidrosis in children and adolescents (ages 6-18) and young adults (ages 18-30). Poster presented virtually at the 2021 Society for Adolescent Health & Medicine Annual Meeting; March 10-12, 2021.
Shayesteh A, Persson M, Brulin C, Nylander E. 'Excessive sweating is not a feminine thing': A qualitative study of women's experiences suffering from primary hyperhidrosis. PLoS One. 2021;16(7):e0254689. Published 2021 Jul 15. doi:10.1371/journal.pone.0254689
Starling CT, Nguyen QD, Butler IJ, Numan MT, Hebert AA. Cutaneous manifestations of orthostatic intolerance syndromes. Int J Womens Dermatol. 2021;7(4):471-477. Published 2021 Mar 11. doi:10.1016/j.ijwd.2021.03.003
Toolabi K, Khaki S, Sadeghian E, Lamsehchi N, Elyasinia F. The rate of compensatory sweating and clinical outcomes of selective thoracoscopic sympathectomy (ramicotomy) in patients with primary palmar hyperhidrosis. Arch Neurosci. 2021;8(1):e111026. doi: 10.5812/ans.111026
Vanaclocha V, Guijarro-Jorge R, Saiz-Sapena N, et al. Selective T3-T4 sympathicotomy versus gray ramicotomy on outcome and quality of life in hyperhidrosis patients: a randomized clinical trial. Sci Rep. 2021;11(1):17628. Published 2021 Sep 2. doi:10.1038/s41598-021-96972-7
Yokozeki H, Fujimoto T, Abe Y, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis [published online ahead of print, 2021 Jan 7]. J Dermatol. 2021;10.1111/1346-8138.15668. doi:10.1111/1346-8138.15668
Campanati A, Gregoriou S, Consales V, et al. Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study. Dermatol Ther. 2020;33(6):e14039. doi:10.1111/dth.14039 (Abstract Only)
Chang TN, Chen LW, Lee CP, Chang KH, Chuang DC, Chao YK. Microsurgical robotic suturing of sural nerve graft for sympathetic nerve reconstruction: a technical feasibility study. J Thorac Dis. 2020;12(2):97-104. doi:10.21037/jtd.2019.08.52
Dogru MV, Sezen CB, Girgin O, et al. Is there any relationship between quality of life and the level of sympathectomy in primary palmar hyperhidrosis? Single-center experience. Gen Thorac Cardiovasc Surg. 2020;68(3):273-279. doi:10.1007/s11748-019-01210-7 (Abstract Only)
Gabes M, Jourdan C, Schramm K, Masur C, Abels C, Kamudoni P, Salek S & Apfelbacher C. Hyperhidrosis quality of life index (HidroQol©): further validation and clinical application in patients with axillary hyperhidrosis using data from a phase III randomized controlled trial. British Journal of Dermatology 2020. doi: 10.1111/bjd.19300.
Gorelick J, Friedman A. Diagnosis and management of primary hyperhidrosis: practical guidance and current therapy update. J Drugs Dermatol 19:7 (2020): 217-223. doi: 10.36849/JDD.2020.5162. (Abstract Only)
Hebert AA, Glaser DA, Green L, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study. Pediatr Dermatol. 2020;37(3):490-497. doi:10.1111/pde.14135
Kirsch B, Smith S, Cohen J, Liu PY, Chadha D, Walker P. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blinded trial. J Am Acad Dermatol 82:6 (2020): 1321-1327. doi: 10.1016/j.jaad.2020.02.016. (Abstract Only)
Klein SZ, Hull M, Gillard KK, Peterson-Brandt J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol Ther (Heidelb). 2020;10(6):1299-1314. doi:10.1007/s13555-020-00439-y
Kristensen JK, Vestergaard DG, Swartling C, Bygum A. Association of Primary Hyperhidrosis with Depression and Anxiety: A Systematic Review. Acta Derm Venereol. 2020;100(1):adv00044. Published 2020 Jan 30. doi:10.2340/00015555-3393
Nawrocki S, Cha J. Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol. 2020;82(4):969-979. doi:10.1016/j.jaad.2019.11.042 (Abstract Only)
Parrish C, Waldbaum B, Coleman D, et al. Microwave Thermolysis Reduces Generalized and Social Anxiety in Young Adults With Axillary Hyperhidrosis. Lasers Surg Med. 2020;52(9):842-847. doi:10.1002/lsm.23229 (Abstract Only)
Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Hebert AA. Characterization of disease awareness and coping strategies in primary focal hyperhidrosis: qualitative focus group results in children, adolescents, and young adults. Poster presented virtually at the 45th Annual Meeting of the Society for Pediatric Dermatology July 2020.
Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard KK, Devlin T, Hebert AA. Quality of life impact of primary focal hyperhidrosis: qualitative focus group results in children, adolescents, and young adults. Poster presented virtually at the 45th Annual Meeting of the Society for Pediatric Dermatology July 2020.
Rice ZP, Pieretti LJ, Wheeler A, Payne J, Gillard K, Devlin T, Hebert AA. Quality of life impact and awareness of primary focal hyperhidrosis in children and adolescents. Poster presented virtually at the Maui Derm Connect Nurse Practitioners and Physician Assistants Fall 2020 Conference September 2020.
Rummaneethorn P, Chalermchai T. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis. Lasers Med Sci. 2020;35(5):1179-1184. doi:10.1007/s10103-020-02958-8 (Abstract Only)
Trettin B, Hansen J, Bygum A. The impact of adolescents' everyday life experiences on their primary hyperhidrosis treatment - a qualitative study [published online ahead of print, 2020 Jul 22]. J Dermatolog Treat. 2020;1-7. doi:10.1080/09546634.2020.1789541
Trindade de Almeida AR, Fonseca Noriega L, Bechelli L, Suarez MV. Randomized controlled trial comparing the efficacy and safety of two injection techniques of incobotulinumtoxinA for axillary hyperhidrosis. J Drugs Dermatol 19:7 (2020): 765-770. doi: 10.36849/JDD.2020.4989. (Abstract Only)
Wolosker N, Kauffman P, de Campos JRM, et al. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases. Int J Dermatol. 2020;59(6):709-715. doi:10.1111/ijd.14872 (Abstract Only)
Cohen SR, Goodacre AK, Leong TS, Southwell L, Nomachi T. Short-Term Clinical Outcomes and Safety Associated With Percutaneous Radiofrequency Treatment for Excessive Sweating. Aesthet Surg J. 2019;39(12):1390-1399. doi:10.1093/asj/sjy277 (Abstract Only)
Dobosz L, Stefaniak T. Evaluation of Quality of Life: Functional Assessment of Chronic Illness Therapy after Thoracic Sympathectomy for Palmar Hyperhidrosis. Thorac Cardiovasc Surg. 2019;67(5):420-424. doi:10.1055/s-0038-1642029 (Abstract Only)
Gibbons M, Armbrecht E, Glaser DA. Primary axillary hyperhidrosis: do gravimetric measurements of sweat production correlate with disease severity or patient characteristic? Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Gollins CE, Carpenter A, Steen C, Bulinski H, Mahendran R. A retrospective analysis of the use of tap water iontophoresis for focal hyperhidrosis at a district general hospital: the patients' perspective. J Dermatolog Treat. 2019 Jan 16:1-9. doi: 10.1080/09546634.2019.1569751. (Abstract Only)
Glaser DA, Green L, Drew J, Gopalan R, Pariser DM. Topical glycopyrronium tosylate improves axillary hyperhidrosis across a broad spectrum of patients: post hoc analyses of the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials in patient subpopulations. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Glaser DA, Hebert AA, Nast A, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol 20 (2019): 593-604.
Glaser EN, Armbrecht ES, King R, Glaser DA. Prevalence of anxiety, depression and attention deficit disorder (ADD) in patients with primary hyperhidrosis. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions. Clin Cosmet Investig Dermatol. 2019;12:733-744. Published 2019 Oct 4. doi:10.2147/CCID.S210973
Hajjar WM, Al-Nassar SA, Al-Sharif HM, et al. The quality of life and satisfaction rate of patients with upper limb hyperhidrosis before and after bilateral endoscopic thoracic sympathectomy. Saudi J Anaesth. 2019 Jan-Mar;13(1):16-22. doi: 10.4103/sja.SJA_335_18.
Hebert AA, Glaser DA, Ballard AM, Pieretti LJ, Pariser DM. Voice of the hyperhidrosis patient: symptoms, impacts and treatments. Insights from large, open, FDA-attended meeting. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Kanni T, Agiasofitou E, Markantoni V, et al. Cryoanalgesia with a CoolSense Device in Patients Treated with Botulinum Toxin-A for Palmar-Plantar Hyperhidrosis: A Self-Controlled Study. Skin Appendage Disord. 2019;5(2):119-120. doi:10.1159/000492239
Lain EL, Glaser DA, Gopalan R, Yan V, Drew J, Pariser DM. Long-term response with topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis according to double-blind treatment group. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Nawrocki S, Cha J. The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part II. Therapeutic options. J Am Acad Dermatol. 2019 Jan 30. pii: S0190-9622(19)30167-7. doi: 10.1016/j.jaad.2018.11.066. (Abstract Only)
Nawrocki S, Cha J. The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part I. Etiology and clinical work-up. J Am Acad Dermatol. 2019 Jan 30. pii: S0190-9622(19)30168-9. doi: 10.1016/j.jaad.2018.12.07. (Abstract Only)
Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: etiology and clinical work-up. Journal of the American Academy of Dermatology 81:3 (2019): 657-666.
Pariser DM, Drew J, Gopalan R, Hebert AA. An evaluation of anticholinergic adverse events with long-term use of topical glycopyrronium tosylate, a treatment for primary axillary hyperhidrosis. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Ribeiro Santos Morard M, Betanho Martins R, Lopes Ribeiro AC, Guimarães Rocha Lima P, Dos Santos Carvalho B, Junior JCBS. Primary hyperhidrosis prevalence and characteristics among medical students in Rio de Janeiro. PLoS One. 2019;14(9):e0220664. Published 2019 Sep 13. doi:10.1371/journal.pone.0220664
Scotelaro-Alves HG, Fernandes NC, Ramos-E-Silva M. Clinical profile of recurrent vesicular palmoplantar dermatitis in children and adolescents. Clin Cosmet Investig Dermatol. 2019 Jan 3;12:23-28. doi: 10.2147/CCID.S150778.
Schreiner W, Mykoliuk I, Dudek W, Sirbu H. Impact of selective quality of life analysis in patients with local hyperhidrosis after sympathicus clipping. Zentralbl Chir. 2019 Feb 22. doi: 10.1055/a-0808-5003 (Abstract Only)
Shim DH, Nguyen TT, Park PG, et al. Development of Botulinum Toxin A-Coated Microneedles for Treating Palmar Hyperhidrosis. Mol Pharm. 2019;16(12):4913-4919. doi:10.1021/acs.molpharmaceut.9b00794 (Abstract Only)
Sidiropoulou P, Gregoriou S, Balaskas E, et al. Managing pitted keratolysis through hyperhidrosis control with topical glycopyrrolate 2%. Poster presented at the 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, DC.
Akil A, Semik M, Fischer S. Efficacy of miniuniportal video-assisted thoracoscopic selective sympathectomy (ramicotomy) for the treatment of severe palmar and axillar hyperhidrosis. Thorac Cardiovasc Surg. 2018 May 8. doi: 10.1055/s-0038-1642030. (Abstract Only)
Bernhard MK, Krause M, Syrbe S. Sweaty feet in adolescents-early use of botulinum type A toxin in juvenile plantar hyperhidrosis. Pediatr Dermatol. 2018 Nov;35(6):784-786. doi: 10.1111/pde.13628. (Abstract Only)
Chilukuri S, Robb CW, Weiner SF, Grossman J. Primary Axillary Hyperhidrosis Treatment Using High Intensity Focused Fractional Radiofrequency Microneedling. J Drugs Dermatol. 2018;17(7):745-748. (Abstract Only)
Cohen SR, Goodacre AK, Leong TS, Southwell L, Nomachi T. Short-term clinical outcomes and safety associated with percutaneous radiofrequency treatment for excessive sweating. Aesthet Surg J. 2018 Dec 9. doi: 10.1093/asj/sjy277. (Abstract Only)
Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019 Jan;80(1):128-138.e2. doi: 10.1016/j.jaad.2018.07.002. Epub 2018 Jul 10.
Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience with Hyperhidrosis: A National Survey of 1,985 Patients. Journal of Drugs in Dermatology 2018 17(4):392-396.
Glaser D et al. Open-label study evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis (ARIDO). Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Hebert AA, Glaser DA, Green L, et al. Short- and long-term efficacy and safety of glycopyrronium cloth for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analyses from the phase 3 studies. Presented at the 37th Fall Clinical Dermatology Conference October 2018.
Hebert A et al. Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: pediatric subgroup analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Hebert AA, Glaser DA, Green L, et al. Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials.
Pediatr Dermatol. 2018;00:1-11. doi: 10.1111/pde.13723.
Horslen LC, Wilshire CL, Louie BE, Vallières E. Long-Term Impact of Endoscopic Thoracic Sympathectomy for Primary Palmar Hyperhidrosis. Ann Thorac Surg. 2018 Oct;106(4):1008-1012. doi: 10.1016/j.athoracsur.2018.04.063. Epub 2018 Jun 7. (Abstract Only)
Leiderman DB, Yazbec G, Wolosker N. Management of compensatory hyperhidrosis. Hyperhidrosis. de Paula Loureiro M, de Campos JR, Wolosker N, Kauffman P (ed): Springer International Publishing, Cham; 2018. 197-202. doi: 10.1007/978-3-319-89527-7_26 (Abstract Only)
Li DC, Hulbert A, Waldbaum B, et al. Endoscopic thoracic sympathectomy for primary focal hyperhidrosis: impact on psycho-social symptomatology and psychotropic medication use. Eur J Cardiothorac Surg. 2018;54(5):904-911. doi:10.1093/ejcts/ezy211
Lubarda J, Dermer S, Maeglin J, Young M, Pariser D. Hyperhidrosis clinical practice patterns and barriers: how do physicians perform? Presented at the 27th European Academy of Dermatology and Venereology Congress September 2018.
López-López D, Becerro-de-Bengoa-Vallejo R, Losa-Iglesias ME, Rodríguez-Sanz D, Palomo-López P, Calvo-Lobo C. Relationship between depression scores and degree of skin perspiration: A novel cross-sectional study. Int Wound J. 2019 Feb;16(1):139-143. doi: 10.1111/iwj.13004.
Mirkovic SE, Rystedt A, Balling M, Swartling C. Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin. Acta Derm Venereol. 2018;98(1):103-107. doi:10.2340/00015555-2755 (Abstract Only)
Pariser DM, Hebert AA, Drew J, Quiring J, Gopalan R, Glaser DA. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials. Am J Clin Dermatol. 2018 Oct 30. doi: 10.1007/s40257-018-0395-0.
Pariser D et al. Topical glycopyrronium tosylate (DRM04) for the treatment of primary axillary hyperhidrosis: pooled results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Pariser D et al. Glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: prior treatment analyses from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Presented at the 76th Annual Meeting of the American Academy of Dermatology February 2018.
Simes BC, Moore JP, Brown TC, Rushforth TJ, Bookout AL, Richardson CL. Genetic polymorphism analysis of patients with primary hyperhidrosis. Clin Cosmet Investig Dermatol. 2018;11:477-483. Published 2018 Oct 11. doi:10.2147/CCID.S176842
Stern J, Zhu S, Blow I, Johnson D. The efficacy of the BedJet Climate System® for peri-menopausal night sweat and hot flash symptoms and corresponding impact on sleep. Presented at the 29th Annual Meeting of the North American Menopause Society; October 3-6, 2018; San Diego, CA.
Artzi O, Loizides C, Zur E, Sprecher E. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study. Acta Derm Venereol. 2017;97(9):1120-1124. doi:10.2340/00015555-2731
Elalfy K, Emile S, Elfeki H, Elmetwally A, Farag M, Gado W. Sequential Extended Thoracoscopic Sympathicotomy for Palmo-Axillo-Plantar Hyperhidrosis. Ann Thorac Surg. 2017;104(4):1200-1207. doi:10.1016/j.athoracsur.2017.04.035 (Abstract Only)
Glaser D et al. Open-label study (ARIDO) evaluating long-term safety of topical glycopyrronium tosylate (GT) in patients with primary axillary hyperhidrosis. Presented at the 36th Fall Clinical Dermatology Conference October 2017.
Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. PM R. 2017;9(4):415-418. doi:10.1016/j.pmrj.2016.10.009 (Abstract Only)
Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population. Abstract (5192) presented at American Academy of Dermatology March 2017, Late-Breaking Research: Clinical Studies/Pediatric (F072).
Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health and Quality of Life Outcomes. 2017 15:121.
Kargi AB. Plantar Sweating as an Indicator of Lower Risk of Compensatory Sweating after Thoracic Sympathectomy. Thorac Cardiovasc Surg. 2017 Sep;65(6):479-483. doi: 10.1055/s-0036-1579680. Epub 2016 Apr 4. (Abstract Only)
Mula KN, Winston J, Pace S, Kentosh JB. Use of a Microwave Device for Treatment of Amputation Residual Limb Hyperhidrosis. Dermatol Surg. 2017;43(1):149-152. doi:10.1097/DSS.0000000000000837 (Abstract Not Available)
Pariser D, Krishnaraja J, Tremblay T, Rubison M, Love T, McGraw B. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis. Journal of Drugs in Dermatology 2017 Feb 1;16(2): 127-132.
Pariser D, Hebert A, Drew J, Quiring J, Glaser D. Patient-reported outcomes from two randomized, double-blind, vehicle-controlled phase 3 trials in axillary hyperhidrosis (ATMOS-1 & ATMOS-2). Presented at the 26th European Academy of Dermatology and Venereology Congress September 2017.
Pariser D et al. DRM04 for the treatment of primary axillary hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Poster 4834 presented at the 75th Annual Meeting of the American Academy of Dermatology March 2017.
Shayesteh A, Janlert U, Nylander E. Hyperhidrosis - Sweating Sites Matter: Quality of Life in Primary Hyperhidrosis according to the Sweating Sites Measured by SF-36. Dermatology. 2017;233(6):441-445. doi:10.1159/000486713 (Abstract Only)
Dharmaraj B, Kosai NR, Gendeh H, Ramzisham AR, Das S. A Prospective Cohort Study on Quality of Life after Endoscopic Thoracic Sympathectomy for Primary Hyperhidrosis. Clin Ter. 2016 May-Jun;167(3):67-71. doi: 10.7417/CT.2016.1928. (Abstract Only)
Dias LI, Miranda EC, Toro IF, Mussi RK. Relationship between anxiety, depression and quality of life with the intensity of reflex sweating after thoracoscopic sympathectomy for treatment of primary hyperhidrosis. Rev Col Bras Cir. 2016;43(5):354-359. doi:10.1590/0100-69912016005013 (Abstract Only)
Glaser D, Ballard A, Hunt N, Pieretti L & Pariser D. Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey. Dermatol Surg 42:12 (2016): 1347-1353.
Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. American Academy of Physical Medicine and Rehabilitation. 2016 Oct 22. pii: S1934-1482(16)31056-5.
Hynes CF, Marshall MB. Reversibility of Sympathectomy for Primary Hyperhidrosis. Thorac Surg Clin. 2016 Nov;26(4):421-426. doi: 10.1016/j.thorsurg.2016.06.006. Epub 2016 Aug 4. Review. (Abstract Only)
Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al. Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver. PLoS One doi: 10.1371/journal.pone.0153719. Published online April 22, 2016.
Muthusamy A, Gajendran R, Ponnan S, Thangavel D, Rangan V. A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(6):CC08-CC10.
Pariser D et al. DRM04 for the treatment of axillary hyperhidrosis: primary results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Late Breaking News D3T01.1 presented at the 25th European Academy of Dermatology and Venereology Congress October 2016.
Pasquina PF, Perry BN, Alphonso AL, Finn S, Fitzpatrick KF, Tsao JW. Residual Limb Hyperhidrosis and RimabotulinumtoxinB: A Randomized Placebo-Controlled Study. Arch Phys Med Rehabil. 2016;97(5):659-664.e2. doi:10.1016/j.apmr.2015.12.027 (Abstract Only)
Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal adults. JAMA Neurol. doi:10.1001/jamaneurol.2016.0508. Published online April 18, 2016.
Shahram M, Hassan Ali M, Mohammad Javad B, Reza M: Up-to-date treatments of primary hyperhidrosis with focus on sympathectomy and sympathicotomy; a narrative review. Hosp Pract Res. 2016; 1:3-7. doi:10.20286/hpr-01013
Shi LL, Sargen MR, Chen SC, Arbiser JL, Pollack BP. Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation. Dermatol Online J. 2016;22(6):13030/qt38b203d0. Published 2016 Jun 15. (Abstract Only)
Abtahi-Naeini B, Naeini FF, Adibi N, Pourazizi M. Quality of life in patients with primary axillary hyperhidrosis before and after treatment with fractionated microneedle radiofrequency. J Res Med Sci. 2015;20(7):631-635. doi:10.4103/1735-1995.166196
Huang H, Hohler AD. The Dermatological Manifestations of Postural Tachycardia Syndrome: A Review with Illustrated Cases. Am J Clin Dermatol. 2015;16(5):425-430. doi:10.1007/s40257-015-0144-6 (Abstract Only)
Jeong JY, Park SS, Sim SB, et al. Prediction of compensatory hyperhidrosis with botulinum toxin A and local anesthetic. Clin Auton Res. 2015;25(4):201-205. doi:10.1007/s10286-015-0288-8 (Abstract Only)
Kouris A, Armyra K, Stefanaki C, Christodoulou C, Karimali P, Kontochristopoulos G. Quality of life and social isolation in Greek adolescents with primary focal hyperhidrosis treated with botulinum toxin type A: a case series. Pediatr Dermatol. 2015;32(2):226-230. doi:10.1111/pde.12480 (Abstract Only)
Lezanski-Gujda A, Bingham JL, Logemann NF. Botulinum toxin: An effective treatment for prosthesis-related hyperhidrosis in patients with traumatic amputations. Indian Dermatol Online J. 2015;6(1):1-3. doi:10.4103/2229-5178.148906
Rieger R, Pedevilla S, Lausecker J. Quality of life after endoscopic lumbar sympathectomy for primary plantar hyperhidrosis. World J Surg. 2015;39(4):905-911. doi:10.1007/s00268-014-2885-4 (Abstract Only)
Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, et al. (2015). Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. British Journal of Dermatology, 173: 1163-1168. doi: 10.1111/bjd.13973
Baroncello JB, Baroncello LR, Schneider EG, Martins GG. Evaluation of quality of life before and after videothoracoscopic simpathectomy for primary hyperhidrosis. Rev Col Bras Cir. 2014;41(5):325-330. doi:10.1590/0100-69912014005005 (Abstract Only)
Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 13:4 (2014): 449-456.
Gross KM, Schote AB, Schneider KK, Schulz A, Meyer J. Elevated social stress levels and depressive symptoms in primary hyperhidrosis. PLoS One. 2014;9(3):e92412. Published 2014 Mar 19. doi:10.1371/journal.pone.0092412
Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of Life in Patients with Focal Hyperhidrosis before and after Treatment with Botulinum Toxin A. ISRN Dermatol. 2014;2014:308650. Published 2014 Feb 6. doi:10.1155/2014/308650
Lessa Lda R, Luz FB, De Rezende RM, et al. The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology. J Psychiatr Pract. 2014;20(4):316-323. doi:10.1097/01.pra.0000452570.69578.31 (Abstract Only)
Pinson I et al. Non-invasive short-wave guided radiofrequency device for long-term sweat reduction in patients with primary axillary hyperhidrosis: a preliminary study, presented at the 34 ASLMS Annual Conference, April 4-6, 2014, Phoenix, AZ.
Spenser, Samantha. From the Patient's Perspective: Traveling Far and Wide to Better Understand, Care For, and Cope with Hyperhidrosis. Journal of Dermatology for Physician Assistants. Vol. 8, No. 4, Fall 2014.
Wolosker N, Schvartsman C, Krutman M, et al. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol. 2014;31(1):48-53. doi:10.1111/pde.12142 (Abstract Only)
Coveliers H, Meyer M, Gharagozloo F, Wisselink W. Selective sympathectomy for hyperhidrosis: technique of robotic transthoracic selective postganglionic efferent sympathectomy. Eur J Cardiothorac Surg. 2013;43(2):428-430. doi:10.1093/ejcts/ezs411
Coveliers H, Meyer M, Gharagozloo F, et al. Robotic selective postganglionic thoracic sympathectomy for the treatment of hyperhidrosis. Ann Thorac Surg. 2013;95(1):269-274. doi:10.1016/j.athoracsur.2012.08.013
El Kahky HM, Diab HM, Aly DG, Farag NM. Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis. Dermatol Res Pract. 2013;2013:686329. doi:10.1155/2013/686329
Ibrahim O, Kakar R, Bolotin D, et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol. 2013;69(1):88-95. doi:10.1016/j.jaad.2013.02.013 (Abstract Only)
Kuijpers M, Klinkenberg TJ, Bouma W, DeJongste MJ, Mariani MA. Single-port one-stage bilateral thoracoscopic sympathicotomy for severe hyperhidrosis: prospective analysis of a standardized approach. J Cardiothorac Surg. 2013;8:216. Published 2013 Nov 26. doi:10.1186/1749-8090-8-216
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Aug;6(80): 811-21.
Wolosker N, Krutman M, Teivelis MP, et al. Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis. Ann Vasc Surg. 2014;28(4):970-976. doi:10.1016/j.avsg.2013.07.032 (Abstract Only)
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 38 (2012): 185-191.
Kern KU, Kohl M, Seifert U, Schlereth T. Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use? Schmerz. 2012;26(2):176-184. doi:10.1007/s00482-011-1140-2 (Abstract Only)
Swaile DF et al. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol 166 Suppl. 1 (2012): 22-26.
Coveliers H, Atif S, Rauwerda J, Wisselink W. Endoscopic thoracic sympathectomy: long-term results for treatment of upper limb hyperhidrosis and facial blushing. Acta Chir Belg. 2011 Sep-Oct;111(5):293-7. (Abstract Only)
Kern U, Kohl M, Seifert U, Schlereth T. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil. 2011;90(4):321-329. doi:10.1097/PHM.0b013e31820636fd (Abstract Only)
Smidfelt K, Drott C. Late results of endoscopic thoracic sympathectomy for hyperhidrosis and facial blushing. Br J Surg. 2011 Dec;98(12):1719-24. doi: 10.1002/bjs.7682. Epub 2011 Sep 16. (Abstract Only)
Vazquez LD, Staples NL, Sears SF, Klodell CT. Psychosocial functioning of patients after endoscopic thoracic sympathectomy. Eur J Cardiothorac Surg. 2011;39(6):1018-1021. doi:10.1016/j.ejcts.2011.01.059
Vergilis-Kalner IJ. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature. J Drugs Dermatol. 2011;10(9):1013-1015. (Abstract Only)
Wang F et al. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 124:21 (2011): 3495-3498.
Woolery-Lloyd H, Valins W. Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis. Cutis 88:1 (2011): 43-45.
Aydin F, Pancar GS, Senturk N, et al. Axillary hair removal with 1064-nm Nd:YAG laser increases sweat production. Clin Exp Dermatol. 2010;35(6):588-592. doi:10.1111/j.1365-2230.2009.03638.x (Abstract Only)
Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treatment of axillary hyperhidrosis, presented at the 2010 ASDS/ASCDAS Joint Annual Meeting, October 21-24, 2010, Chicago, IL.
Kaminer MS et al. First clinical use of a novel microwave device for treatment of axillary hyperhidrosis, presented at the American Society for Dermatologic Surgery 2010 Annual Meeting, October 21-24, 2010, Chicago, IL.
Marques AH et al. Evaluation of stress symptoms by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. Neuroimmunomodulation 17:3 (2010): 205-208.
Milanez de Campos JR et al. Comparison of pain severity following video-assisted thoracoscopic sympathectomy: electric versus harmonic scalpels. Interactive Cardiovascular and Thoracic Surgery 10 (2010): 919-922.
Prasad A et al. Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Surg Endosc 24 (2010): 1952-1957.
Shams K, Kavanagh GM. Immediate reduction in sweat secretion with electric current application in primary palmar hyperhidrosis. Archdermatol doi: 10.1001/archdermatol.2010.300.
Wait SD. et al. Thoracoscopic sympathectomy for hyperhidrosis: analysis of 642 procedures with special attention to horner’s syndrome and compensatory hyperhidrosis. Neurosurgery 67:3 (2010): 652-657.
Wolosker N et al. Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis. Journal of Vascular Surgery 51:5 (2010): 1190-1194.
Fibla JJ, Molins L, Mier JM, Vidal G. Effectiveness of sympathetic block by clipping in the treatment of hyperhidrosis and facial blushing. Interact Cardiovasc Thorac Surg. 2009;9(6):970-972. doi:10.1510/icvts.2009.212365
Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. Journal of Drugs in Dermatology 8:5 (2009): 477-480.
Jones T et al. Safety and tolerability of topical botulinum toxin type A in healthy adults, presented at the 69th Annual Meeting of the Society for Investigative Dermatology, May 2009, Montreal, Canada.
Martins Rua JF, Jatene FB, de Campos JR, et al. Robotic versus human camera holding in video-assisted thoracic sympathectomy: a single blind randomized trial of efficacy and safety. Interact Cardiovasc Thorac Surg. 2009;8(2):195-199. doi:10.1510/icvts.2008.191353
Ng S et al. Management of Frey syndrome using botulinum neurotoxin: a case report. JCDA 75:9 (2009): 651-654.
Prehn-Kristensen A et al. Induction of empathy by the smell of anxiety. PLoS One doi: 10.1371/journal.pone.0005987.
Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol. 2008;7(1):50-54. doi:10.1111/j.1473-2165.2008.00361.x (Abstract Only)
Efthymiou CA, Thorpe JAC. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. European Journal of Cardio-thoracic Surgery 33 (2008): 1157-1158.
Flanagan KH et al. Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. Journal of Drugs in Dermatology 7:3 (2008): 221-227.
Smalls LK et al. Clinical comparison of otc products labeled prescription strength wetness protection to prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Smalls LK et. al. Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.
Walles T, Somuncuoglu G, Steger V, Veit S, Friedel G. Long-term efficiency of endoscopic thoracic sympathicotomy: survey 10 years after surgery. Interact Cardiovasc Thorac Surg. 2009 Jan;8(1):54-7. doi: 10.1510/icvts.2008.185314. Epub 2008 Sep 30. (Abstract Only)
Charrow A, DiFazio M, Foster L, Pasquina PF, Tsao JW. Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series. Arch Phys Med Rehabil. 2008;89(7):1407-1409. doi:10.1016/j.apmr.2007.11.054 (Abstract Only)
Glaser DA et al. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Glaser DA et al. 4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Malmivaara A, Kuukasjärvi P, Autti-Ramo I, Kovanen N, Mäkelä M. Effectiveness and safety of endoscopic thoracic sympathectomy for excessive sweating and facial blushing: a systematic review. Int J Technol Assess Health Care. 2007 Winter;23(1):54-62. Review. (Abstract Only)
Naumann M, Hamm H, Kinkelin I, Reineis K. Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions. European Journal of Neurology. 2007; https://doi.org/10.1111/j.1468-1331.1999.tb00027.x.(Abstract Only)
Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. Dermatol Surg 33 (2007): 908-923.
Talarico-Filho S et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 (2007): S44-S50.
Thomas M et al. Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.
Moya J et al. Thoracic sympathicolysis for primary hyperhidrosis. Surg Endosc 20 (2006): 598-602.
Pariser D et al. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Thomas M et al. Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.
Boboschko I, Jockenhöfer S, Sinkgraven R, Rzany B. Hyperhidrose als Risikofaktor der Tinea pedis [Hyperhidrosis as risk factor for tinea pedis]. Hautarzt. 2005;56(2):151-155. doi:10.1007/s00105-004-0849-6 (Abstract Only)
Glaser DA et al. Effect of repeated botulinum toxin type A treatment on health related quality of life and functioning in patients with primary axillary hyperhidrosis: results from 2 years of longitudinal data, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Glaser DA et al. Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Haider A, Solish N.Focal hyperhidrosis: diagnosis and management. CMAJ 172:1 (2005): 1-7.
Kowalski JW et al. Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Ogata A, et al. Low and high frequency acupuncture stimulation inhibits mental stress-induced sweating in humans via different mechanisms. Auton Neurosci 118: 1-2 (2005): 93-101.
Solish N et al. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:4 (2005): 405-413.
Swaile D, Chabi G, Putnam C. Clinical comparison of antiperspirant efficacy as a function of morning and/or nighttime application, presented at ACADEMY '05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.
Weber A et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. British Journal of Dermatology, (2005) 152: 342–345.
Campanati A et al. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.
Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Glaser DA et al. Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (English, without graphs)
Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (German, with graphs)
Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Movement Disorders. 2004; https://doi.org/10.1002/mds.20067. (Abstract Only)
Strutton D et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.
Blaheta H, Deusch H, Rassner G, Vollert B. Intravenous regional anesthesia (Bier's block) is superior to a peripheral nerve block for painless treatment of plantar hyperhidrosis with botulinum toxin. J Am Acad Dermatol 48:2 (2003): 302-304.
de Campos JR, Kauffman P, Werebe Ede C, et al. Quality of life, before and after thoracic sympathectomy: report on 378 operated patients. Ann Thorac Surg. 2003;76(3):886-891. doi:10.1016/s0003-4975(03)00895-6 (Abstract Only)
Goodman, G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. Dermatol Surg 29:5 (2003): 533-538.
Naumann, M et al. Comparing the quality of life effect of primary focal hyperhidrosis to other dermatological conditions as assessed by the dermatology life quality index (DLQI). Value In Health, The Journal of The International Society for Pharmacoeconomics and Outcomes Research 6:3 (2003): 242.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041-1045. doi:10.1111/j.1365-2133.2003.05620.x
Chuang K, Liu J. Long-term assessment of percutaneous sterotactic thermocoagulation of upper thoracic ganglionectomy and sympathectomy for palmar and craniofacial hyperhidrosis in 1742 cases. Neurosurgery 51:4 (2002): 963-969.
Wollina U, Karamfilov T. Botulinum toxin A for palmar hyperhidrosis. Journal of The European Academy of Dermatology and Venereology. 2002; https://doi.org/10.1046/j.1468-3083.2001.00350.x(Abstract Only)
Swartling C, Farnstrand C, Abt G, Stalberg E, Naver H. Side effects of intradermal injections of botulinum A toxin in the treatment of palmar hyperhidrosis: a neurophysiological study. European Journal of Neurology 8 (2001): 451-456.
Manca D, Valls-Sole J, Callejas M. Excitability recovery curve of the sympathetic skin response in healthy volunteers and patients with palmar hyperhidrosis. Clinical Neurophysiology 111 (2000): 1767-1770.
Reisfeld R, Nguyen R, Pnini A. Endoscopic thoracic sympathectomy for treatment of essential hyperhidrosis syndrome: experience with 650 patients. Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):5-10. (Abstract Only)
Rex L, Drott C, Claes G, Gothberg G, Dalman P. The Boras experience of endoscopic thoracic sympathicotomy for palmar, axillary, facial hyperhidrosis and facial blushing. Eur J Surg 164:Suppl 580 (1998): 23-26.
Noppen M, Sevens C, Gerlo E, Vincken W. Plasma catecholamine concentrations in essential hyperhidrosis and effects of thoracoscopic D2-D3 sympathicolysis. European Journal of Clinical Investigation 27 (1997): 202-205.
Sampaio C, Ferreira JJ, Simões F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013-1018. doi:10.1002/mds.870120627 (Abstract Only)
Drott C, Gothberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. Journal of the American Academy of Dermatology 33:1 (1995): 78-81.
Orteu C, McGregor J, Almeyda J, Rustin M. Recurrence of hyperhidrosis after endoscopic transthoracic sympathectomy—case report and review of the literature. Clinical and Experimental Dermatology 20 (1995): 230-233.
Reinauer S, Neusser A, Schauf G, Holzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. British Journal of Dermatology 129 (1993): 166-169.
Reinauer S, Schauf G, Holzle E. Ross syndrome: treatment of segmental compensatory hyperhidrosis by a modified iontophoretic device. Journal of the American Academy of Dermatology 28:2 (1993): 308-312.
Laccourreye O, Bonan B, Brasnu D, Laccourreye H. Treatment of Frey's syndrome with topical 2% diphemanil methylsulfate (Prantal®): a double-blind evaluation of 15 patients. Laryngoscope 100 (1990): 651-653.
Glent-Madsen L, Dahl JC. Axillary hyperhidrosis: local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 (1988): 87-89.
Tashjian E, Richter K. The value of propoxyphene hydrochloride (darvon) for the treatment of hyperhidrosis in the spinal cord injured patient: an anecdotal experience and case reports. Paraplegia 23 (1985): 349-353.